Anti-beta glucan antibodies represent a mechanism-based biomarker to select patients responsive to the novel immunotherapeutic, Imprime PGG. (December 2016) - Bose, N.; Ottoson, N.; Harrison, B.; Chan, A.; Bykowski Jonas, A.; Qiu, X.; Ma, M.; Huhn, R.; Lowe, J.; Walsh, R.; Gorden, K.; Leonardo, S.; et al.